Evidence map›Paper›PMID 28574799›Full record

ArticleNucleosides, nucleotides & nucleic acids2017

A novel entecavir analogue constructing with a spiro[2.4]heptane core structure in the aglycon moiety: Its synthesis and evaluation for anti-hepatitis B virus activity.

Hiroki Kumamoto, Misato Fukano, Shuhei Imoto, Satoru Kohgo, Yuki Odanaka, Masayuki Amano, Nobuyo Kuwata-Higashi, Hiroaki Mitsuya, Kazuhiro Haraguchi, Kiyoshi Fukuhara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nucleosides, nucleotides & nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hiroki Kumamotoa School of Pharmacy , Showa University , Shinagawa-ku , Tokyo , Japan.
Misato Fukanoa School of Pharmacy , Showa University , Shinagawa-ku , Tokyo , Japan.
Shuhei Imotob Faculty of Pharmaceutical Sciences , Sojo University , Kumamoto , Japan.
Satoru Kohgoc Cinical Research Center, National Center for Global Health and Medicine , Tokyo , Japan.
Yuki Odanakaa School of Pharmacy , Showa University , Shinagawa-ku , Tokyo , Japan.
Masayuki Amanod Departments of Infectious Diseases and Hematology , Kumamoto University School of Medicine , Kumamoto , Japan.
Nobuyo Kuwata-Higashic Cinical Research Center, National Center for Global Health and Medicine , Tokyo , Japan.
Hiroaki Mitsuyac Cinical Research Center, National Center for Global Health and Medicine , Tokyo , Japan.
Kazuhiro Haraguchif Nihon Pharmaceutical University , Saitama , Japan.
Kiyoshi Fukuharaa School of Pharmacy , Showa University , Shinagawa-ku , Tokyo , Japan.

Funding

Development of Novel Agents Active against Hepatitis B VirusZIABC011486 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MITSUYA, HIROAKI · 2013 to 2025
$3.0M
Intramural NIH HHS ZIA BC011486
6 · The paper itself

Abstract

Synthesis of a novel 2'-deoxy-guanine carbocyclic nucleoside 4 constructed with spiro[2.4]heptane core structure in the aglycon moiety was carried out. Radical-mediated 5-exo-dig mode cyclization and following cyclopropanation proceeded efficiently to furnish the spiro alcohol 10. Subsequent Mitsunobu-type glycosylation between 13 and 14, deoxygenation of the 2'-hydroxyl group of 16 and deprotection of 17 gave the title compound 4. Compound 4 demonstrated moderate anti-HBV activity (EC

Indexed as

Antiviral AgentsChemistry Techniques, SyntheticGuanineHepatitis B virusHeptanesStructure-Activity RelationshipAntiviral AgentsentecavirGuanineHeptanesAnti-HBVcarbocyclic nucleosideentecavirradical-mediated cyclizationspiro[2.4]heptane

Identifiers

PMID28574799
PMCPMC7900907

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.